AKT1 and melanoma: Hence, the best response to BRAFi/MEKi is seen in V600E-mutated melanomas, followed to a lesser extent by V600K-mutated melanomas in which alternative pathways, such as phosphoinositide (PI) 3-kinas (PIK3-AKT), may gain more importance for tumor proliferation [34].